Tyra Biosciences (TYRA) Income towards Parent Company (2020 - 2026)
Tyra Biosciences (TYRA) posted Income towards Parent Company of -$363.7 million for Q1 2026, down 968.75% on a QoQ basis from -$34.0 million in Q4 2025, and down 774.12% year-over-year from $54.0 million in Q1 2025.
Tyra Biosciences (TYRA) Income towards Parent Company (2020 - 2026) Analysis & Trends
Tyra Biosciences' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$363.7 million for Q1 2026.
- Quarterly Income towards Parent Company fell 774.12% year-over-year to -$363.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$515.6 million (down 89.85% YoY) and the FY2025 annual result came in at -$306.6 million, down 154.92% from the prior year.
- Income towards Parent Company was -$363.7 million for Q1 2026 at Tyra Biosciences, down from -$34.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$13.0 million in Q4 2022 and bottomed at -$363.7 million in Q1 2026.
- A 5-year average of -$69.3 million and a median of -$41.9 million in 2025 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2025 — Income towards Parent Company soared 44.54% — and 2026, when it tumbled 774.12%.
- Tyra Biosciences' Income towards Parent Company stood at -$13.0 million in 2022, then tumbled by 76.13% to -$22.8 million in 2023, then retreated by 13.32% to -$25.9 million in 2024, then sank by 31.55% to -$34.0 million in 2025, then plunged by 968.75% to -$363.7 million in 2026.
- Business Quant data shows TYRA's Income towards Parent Company at -$363.7 million in Q1 2026, -$34.0 million in Q4 2025, and -$75.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Tyra Biosciences | 1.95 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -363.74 Mn |
| Dec 31, 2025 | -34.03 Mn |
| Sep 30, 2025 | -75.89 Mn |
| Jun 30, 2025 | -41.89 Mn |
| Mar 31, 2025 | -41.61 Mn |
| Dec 31, 2024 | -25.87 Mn |
| Sep 30, 2024 | -135.01 Mn |
| Jun 30, 2024 | -69.07 Mn |
| Mar 31, 2024 | -75.03 Mn |
| Dec 31, 2023 | -22.83 Mn |
| Sep 30, 2023 | -61.13 Mn |
| Jun 30, 2023 | -70.61 Mn |
| Mar 31, 2023 | -67.78 Mn |
| Dec 31, 2022 | -12.96 Mn |
| Sep 30, 2022 | -31.32 Mn |
| Jun 30, 2022 | -15.17 Mn |
| Mar 31, 2022 | -34.75 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -44.68 Mn |
| Jun 30, 2021 | -5.60 Mn |